期刊文献+

Study on the Pharmacokinetics and Relative Bioavailability of Irbesartan Capsules in Healthy Volunteers 被引量:2

Study on the Pharmacokinetics and Relative Bioavailability of Irbesartan Capsules in Healthy Volunteers
下载PDF
导出
摘要 The pharmacokinetics and relative bioavailability were studied in 18 healthy volunteers. A single oral dose of 150 mg irbesartan capsule (test) or tablet (reference) was given to each volunteer according to a randomized 2 way crossover study. The concentrations in plasma were determined by HPLC UV method. The main parameters of irbesartan capsules were: C max : 1.502±0.295 μg/ml, t max : 1.44±0.34 h, t 1/2 : 20.21±14.71 h, AUC 0 t : 11.087±3.443 μg/ml -1 ·h. The relative bioavailability of capsule to tablet was (101.4±28.9) %. The results of statistical analysis showed that two formulations were bioequivalent. The pharmacokinetics and relative bioavailability were studied in 18 healthy volunteers. A single oral dose of 150 mg irbesartan capsule (test) or tablet (reference) was given to each volunteer according to a randomized 2 way crossover study. The concentrations in plasma were determined by HPLC UV method. The main parameters of irbesartan capsules were: C max : 1.502±0.295 μg/ml, t max : 1.44±0.34 h, t 1/2 : 20.21±14.71 h, AUC 0 t : 11.087±3.443 μg/ml -1 ·h. The relative bioavailability of capsule to tablet was (101.4±28.9) %. The results of statistical analysis showed that two formulations were bioequivalent.
出处 《Journal of Huazhong University of Science and Technology(Medical Sciences)》 SCIE CAS 2002年第1期14-16,共3页 华中科技大学学报(医学英德文版)
关键词 IRBESARTAN PHARMACOKINETICS BIOAVAILABILITY HPLC irbesartan pharmacokinetics bioavailability HPLC
  • 相关文献

参考文献3

  • 1张朝阳,孙兴昌,黄洁,彭北阳,李一石.伊贝沙坦和苯那普利对肾素-醛固酮系统的影响[J].中国临床药理学杂志,2001,17(2):94-95. 被引量:5
  • 2[3]Gillis J C, Markham A. Irbesartan: a review of its pharmacodynamic and pharmacokinetics properties and therapeutic use in the management of hypertension. Drugs,1997,54(6):885
  • 3[4]Vachharajani N N, Shyu W C, Chando T J et al. Oral bioavailability and disposition characteristics of irhesartan, an angiotension antagonist, in healthy volunteers. J Clin Pharmacol, 1998,38:702

二级参考文献5

  • 1[1]Anton H.van den Meiracker, Peter JJ. Admiraal,Joop A. Janssen, et al. Hemodynamic and biochemical effects of the AT1 receptor antagonist Irbesartan in hypertension. Hypertension,1995;25:22~29.
  • 2[2]Weber A. Clinical experience with the angiotensin II receptor antagonist Losartan ; a preliminary report. Am J Hypertens,1992; 5(suppl):247s~251s.
  • 3[3]Menard J, Guyene TT,Chatellier G, et al. Renin release regulation during acute renin inhibition in normal volunteers. Hypertension, 1991;18:257~265.
  • 4[4]Lionl H.Opie. Angiotensin converting enzyme inhibitors. Author, Publishing House, New York, 1994.
  • 5[5]Goldberg MR, Tanaka W, Barchowsky A, et al. Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers. Hypertension,1993;21:704~713..

共引文献4

同被引文献5

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部